Quest Diagnostics' ongoing revamp continued this week with news that an Australian company has snatched up its colorectal cancer screening test business. Neither side is commenting on the financial details.
Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.
The European Commission has stamped an approval on Stivarga (a.k.a. regorafenib) for aggressive cases of colorectal cancer, marking a regulatory victory for Bayer Healthcare and Onyx Pharmaceuticals ($ONXX). Amgen ($AMGN) benefits, too.
San Diego's Advanced Proteomics is gearing up to launch its first diagnostic tests, and now the company has $28 million to get it there thanks to a just-closed Series C.
U.K. scientists have zeroed in on a biomarker that could rapidly identify colorectal cancer patients who need aggressive chemotherapy treatment to prevent metastasis. The biomarker also offers a potential new drug target.
The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market.
Exact Sciences is looking to haul in $63.7 million through a stock sale, cash the company needs to get its stool-based cancer diagnostic through the FDA process and onto U.S. shelves.
Exact Sciences has completed its three-step process to win FDA approval for a stool-based cancer diagnostic, submitting the same data that spooked investors back in April with hopes of convincing the agency.
Exact Sciences stock plunged more than 20% late Thursday morning based on what was ostensibly positive early news about a massive pivotal study for the company's colorectal cancer molecular diagnostic test. While the data met all endpoints, investors clearly wanted better and they punished the company as a result.
Cancer diagnostics startup CvergenX will work jointly with the National Cancer Institute to develop a new diagnostic that would predict the likely success of radiation therapy. The goal is to bring the test to market within three years.